ESMO

News

Cost-Benefit Analysis Shows Difference in Price, Clinical Benefit of Cancer Drugs in US, Europe

05/26/2020

A cost-benefit analysis published in The Lancet Oncology (May 2020;21[5]:664-670) compared the prices and clinical benefit of cancer drugs in the US vs Europe. Both the US and European countries are faced with the...

A...

05/26/2020

Journal of Clinical Pathways

Research in Review

Few RCTs of New Systemic Therapies Met ESMO Guidelines for Meaningful Outcomes

12/13/2016

JCP Editors

Fewer than one-third of randomized controlled trials reporting statistically significant outcomes for novel systemic therapies in solid cancers met the European Society of Medical Oncology’s (ESMO) threshold for...

Fewer...

12/13/2016

Journal of Clinical Pathways

ASCO, ESMO Value Frameworks Imperfectly Apply to Hematology

11/30/2016

JCP Editors

Current value frameworks issued by leading medical societies may not be easily generalizable to the treatment of hematologic malignancies, according to two studies presented at the 2016 ASH Annual Meeting and...

...

11/30/2016

Journal of Clinical Pathways